Last reviewed · How we verify
Candemore Plus Tab
Candemore Plus is a fixed-dose combination of candesartan cilexetil (an angiotensin II receptor blocker) and amlodipine (a calcium channel blocker) that reduces blood pressure through dual vasodilation and renin-angiotensin system inhibition.
Candemore Plus is a fixed-dose combination of candesartan cilexetil (an angiotensin II receptor blocker) and amlodipine (a calcium channel blocker) that reduces blood pressure through dual vasodilation and renin-angiotensin system inhibition. Used for Hypertension.
At a glance
| Generic name | Candemore Plus Tab |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | Angiotensin II receptor blocker / Calcium channel blocker combination |
| Target | AT1 receptor; L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Candesartan blocks angiotensin II type 1 receptors, preventing vasoconstriction and aldosterone secretion, while amlodipine inhibits L-type calcium channels in vascular smooth muscle to promote vasodilation. Together, these complementary mechanisms provide synergistic antihypertensive effects with improved blood pressure control compared to monotherapy.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Peripheral edema
- Headache
- Fatigue
Key clinical trials
- A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy (PHASE4)
- To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure (PHASE4)
- The Study to Evaluate Efficacy and Safety of Candesartan vs Losartan in Hypertension With Heart Failure (HONOR) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Candemore Plus Tab CI brief — competitive landscape report
- Candemore Plus Tab updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI